131 results
424B3
BXRXQ
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
and preclinical studies;
our ability to source materials needed for our product candidates, optimize formulations for stability and other characteristics;
our … share and per share data)
(Unaudited)
On August 26, 2019, TeraImmune entered into the non-exclusive Biological Materials License Agreement (“BML
DEFA14A
BXRXQ
Baudax Bio, Inc.
10 Oct 23
Additional proxy soliciting materials
7:00am
Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … ):
No fee required.
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
PRER14A
nb1i1p4xtp
25 Aug 23
Preliminary revised proxy
4:01pm
8-K
EX-10.1
otw73f2wg6rv
25 Aug 23
Entry into a Material Definitive Agreement
8:03am
DEFA14A
ss454jhqd
21 Aug 23
Additional proxy soliciting materials
8:05am
8-K
EX-10.1
shaualic4jc06p
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
424B5
e10wen o9wdg1zhfk
18 Aug 23
Prospectus supplement for primary offering
4:40pm
DEFA14A
EX-99.1
hn3 bvvnj
9 Aug 23
Additional proxy soliciting materials
5:28pm
DEFA14A
EX-99.2
n6kbohzub
9 Aug 23
Additional proxy soliciting materials
5:28pm
8-K/A
EX-99.2
bot rxjd5t
9 Aug 23
Other Events
5:27pm
8-K/A
EX-99.1
5wzs1a0 jnn7p
9 Aug 23
Other Events
5:27pm